SCHEMBL6297724

SCHEMBL6297724

CC(C)C(=O)C=Cc1nccs1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 1/20 0.47
EGFR P00533 1/20 0.47
MAOA P21397 1/20 0.42
MAOB P27338 1/20 0.42
ALDH1A1 P00352 3/20 0.39
NLRP3 Q96P20 2/20 0.39
RIOK2 Q9BVS4 1/20 0.36
RAB9A P51151 5/20 0.36
ADORA2A P29274 1/20 0.35
SMN1; SMN2 Q16637 5/20 0.34
NPC1 O15118 4/20 0.34
KDM4E B2RXH2 2/20 0.34
NFKB1 P19838 2/20 0.34
NFKB2 Q00653 2/20 0.34
RELA Q04206 2/20 0.34
TP53 P04637 1/20 0.34
KMT2A Q03164 1/20 0.34
LMNA P02545 1/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6297723 1.00 JAK2 (0.47) JAK2EGFRMAOAMAOBALDH1A1
SCHEMBL4573054 0.80 JAK2 (0.50) JAK2EGFRMAOAMAOBALDH1A1
SCHEMBL4573050 0.80 JAK2 (0.50) JAK2EGFRMAOAMAOBALDH1A1
SCHEMBL18250750 0.80 JAK2 (0.49) JAK2EGFRMAOAMAOBALDH1A1
SCHEMBL2783487 0.78 JAK2 (0.48) JAK2EGFRMAOAMAOBALDH1A1
SCHEMBL2783490 0.78 JAK2 (0.48) JAK2EGFRMAOAMAOBALDH1A1
SCHEMBL27246702 0.77 JAK2 (0.47) JAK2EGFRMAOAMAOBALDH1A1
SCHEMBL29611275 0.77 JAK2 (0.47) JAK2EGFRMAOAMAOBALDH1A1
SCHEMBL24149497 0.76 JAK2 (0.47) JAK2EGFRMAOAMAOBALDH1A1
SCHEMBL12530272 0.76 JAK2 (0.47) JAK2EGFRMAOAMAOBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050075390-A1 HIV protease inhibitors AGOURON PHARMACEUTICALS, INC. 2005-04-07 US disclosed
US-6852711-B2 Novel dihydropyrones with tethered heterocycles having improved pharmacologic properties which potently inhibit the HIV aspartyl protease blocking HIV infectivity. The dihydropyrones are useful in the development of therapies for AGOURON PHARMACEUTICALS, INC. (US) 2005-02-08 US disclosed
US-20040106606-A1 HIV protease inhibitors BOYER FREDERICK EARL (US) 2004-06-03 US disclosed
US-6528510-B1 Dihydropyrones with tethered heterocycles; 3-(2-tert-Butyl-4-hydroxymethyl-5-methyl-phenylsulfanyl)-4-hydroxy-6 -isopropyl-6-(2-pyridin-4-yl-ethyl)-5,6-dihydro-pyran - 2-one; WARNER-LAMBERT COMPANY 2003-03-04 US disclosed
EP-1112269-A2 HIV PROTEASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-07-04 EP disclosed
WO-2000015634-A2 HIV PROTEASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2000-03-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106606-A1 HIV protease inhibitors DNPEP, PREP, PEPD JAK2 3828/4885EGFR 4746/4885MAOA 2457/4885
US-20050075390-A1 HIV protease inhibitors DNPEP, PREP, PEPD JAK2 3871/4885EGFR 4760/4885MAOA 2595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.